Studying novel single-domain antibodies (nanobodies) capable of modulating GABA-A receptors with exquisite subtype selectivity, offering a promising alternative to classical small molecule PAMs like BZD. My research aims to further characterise and study such nanobodies, exploring their therapeutic potential; the main focus is to improve their ability to traverse across the blood-brain barrier.
